NHLBI awards Gamma Therapeutics $1.1M grant to study CVD risk assay

Under a $1.1 million Phase II Small Business Innovation Research grant from the National Heart, Lung and Blood Institute (NHLBI), Gamma Therapeutics will complete development, validation and beta testing for its GammaCoeur CVD risk assay.

According to Portland, Ore.-based Gamma Therapeutics, the grant will allow the company to submit a regulatory approval application for the Class II in vitro diagnostic device to the FDA.

The company said that GammaCoeur reiterates the need for a MI and stroke risk biomarker for diagnostic tests used to record cholesterol, triglycerides and glucose levels. GammaCoeur, when approved, will provide cardiologists with a better tool for predicting a patient’s MI risk, according to the company.

Gamma Therapeutics, a diagnostic test and surgical therapy solutions developer, said that it expects the FDA regulatory approval process to take up to two years, and said it expects approval by the end of 2012.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.